ABSTRACT
BACKGROUND Polycystic ovary syndrome (PCOS) is the most common hormone disorder affecting about one in seven reproductive-aged women worldwide and approximately 6 million women in the United States (U.S.). PCOS can be a significant burden to those affected and is associated with an increased prevalence of mental health (MH) disorders such as depression, anxiety, eating disorders, and postpartum depression. We undertook this study to determine the excess economic burden associated with MH disorders in women with PCOS, in order to allow for a more accurate prioritization of the disorder as a public health priority.
METHODS Followed PRISMA reporting guidelines for systematic review, we searched PubMed, Web of Science, EBSCO, Medline, Scopus, and PsycINFO through July 16, 2021, for studies on MH disorders in PCOS. Excluded were studies not in humans, without controls, without original data, or not peer reviewed. As anxiety, depression, eating disorders, and postpartum depression were by far the most common MH disorders assessed by the studies, we performed our meta-analysis on these disorders. Meta-analyses were performed using the DerSimonian-Laird random-effects model to compute pooled estimates of prevalence ratios (PR) for the associations between PCOS and these MH disorders, and then calculated the excess direct costs of related to these disorders in U.S. dollars (USD) for women suffering from PCOS in the U.S. alone. The quality of selected studies was assessed using the Newcastle-Ottawa Scale.
RESULTS We screened 78 articles by title/abstract, assessed 43 articles in full-text, and included 25 articles. Pooled PRs were 1.42 (95% CI: 1.32-1.52) for anxiety, 1.65 (95% CI: 1.44-1.89;) for depression, 1.48 (95% CI: PR: 1.06-2.05) for eating disorders, and 1.20 (95% CI: 0.96-1.50) for postpartum depression, for PCOS relative to controls. In the U.S, the additional direct healthcare costs associated with anxiety, depression and eating disorders in PCOS were estimated to be $1.939 billion/yr., 1.678 billion/yr., and $0.644 billion/yr. in 2021 USD, respectively. Postpartum depression was excluded from the cost analyses due to the non-significant meta-analysis result. Taken together, the additional direct healthcare costs associated with anxiety, depression and eating disorders in PCOS was estimated to be $4.261 billion/yr. in 2021 USD.
CONCLUSIONS Overall, the direct healthcare annual costs for the most common MH disorders in PCOS, namely anxiety, depression, and eating disorders exceeds $4 billion in 2021 USD for the U.S. population alone. Taken together with our prior work, these data suggest that the healthcare-related economic burden of PCOS exceeds $15 billion yearly, considering the costs of PCOS diagnosis, and cost related to PCOS-associated MH, reproductive, vascular, and metabolic disorders. As PCOS has much the same prevalence across the world, the excess economic burden attributable to PCOS globally is enormous, mandating that the scientific and policy community increase its focus on this important disorder.
FUNDING The study was supported, in part, by PCOS Challenge: The National Polycystic Ovary Syndrome Association and by the Foundation for Research and Education Excellence
CLINICAL TRIAL NUMBER N/A
Competing Interest Statement
Surabhi Yadav, Olivia Delau, Adam Bonner, Daniela Markovic, William Patterson, Sasha Ottey, and Richard P. Buyalos, have no competing interests to declare. Ricardo Azziz serves as a consultant for Spruce Bioscience, Core Access Surgical Technology, Rani Therapeutics, and Fortress Biotech, advisor for Arora Forge, and investor in Martin Imaging.
Funding Statement
The study was supported, in part, by PCOS Challenge: The National Polycystic Ovary Syndrome Association and funding from the Foundation for Research and Education Excellence. The authors or their institutions did not at any time received payment or services from a third party for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB was required as the analysis used published data for the meta-analysis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
Data Availability Statement: The data is available at: Azziz, Ricardo. (2022). Economic Burden of Mental Health Disorders in PCOS-Supplementary Data [Data set]. Zenodo. https://doi.org/10.5281/zenodo.7478354
Support: The study was supported, in part, by PCOS Challenge: The National Polycystic Ovary Syndrome Association and the Foundation for Research and Education Excellence
Disclosure Summary: Surabhi Yadav, Olivia Delau, Adam Bonner, Daniela Markovic, and Richard P. Buyalos, have no competing interests to declare. Sasha Ottey received honoraria from Institute for Family Centeredness; has received travel support for attendance at Women’s Health Innovation Summit; and is Executive Director for PCOS Challenge: The National Polycystic Ovary Executive Director Syndrome Association. The author has no other competing interests to declare. William Patterson is a Director of Public Affairs, Study Recruitment and Patient Registry Manager, and Intern Preceptor for PCOS Challenge: The National Polycystic Ovary Syndrome Association. The author has no other competing interests to declare. Ricardo Azziz received a grant from Ferring Pharmaceuticals; has received royalties from Wolters Kluwer Health, Johns Hopkins University Press, Springer, and McGraw Hill; has received honoraria from Davidson-Mestman course; has participated on a data safety monitoring board for University of Michigan and Guangzhou Medical University; has held a leadership or fiduciary role at American Society for Reproductive Medicine; holds stock at Martin Imaging and Arora Forge; has received consulting fees from Spruce Biosciences, Fortress Biotech, Rani Therapeutics, Core Access Surgical for PCOS, female reproduction and gynecologic surgery; and serves as Senior Editor at eLife. The author has no other competing interests to declare.
Data Availability
Surabhi Yadav, Olivia Delau, Adam Bonner, Daniela Markovic, William Patterson, Sasha Ottey, and Richard P. Buyalos, have no competing interests to declare. Ricardo Azziz serves as a consultant for Spruce Bioscience, Core Access Surgical Technology, Rani Therapeutics, and Fortress Biotech, advisor for Arora Forge, and investor in Martin Imaging.
